Dimeric MHC-peptides inserted into an immunoglobulin scaffold as new immunotherapeutic agents

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 9, 2011, Pages 1822-1832

  Goldberg, Burt ^a   Bona, Constantin ^b  

^a NEW YORK UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

CD4 T cells; Dimeric class II peptide molecules; Interleukin 10; Peptides derived from auto antigens; Tr1 regulatory T cells

Indexed keywords

HLA ANTIGEN; IMMUNOGLOBULIN; PEPTIDE;

HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; PROTEIN MULTIMERIZATION; REVIEW;

HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; PEPTIDES; PROTEIN MULTIMERIZATION;

MURINAE;

EID: 80052168618     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01319.x     Document Type: Review

References (55)

1. Davie JM, Paul WE. Antigen-binding receptors on lymphocytes. Contemp Top Immunobiol. 1974; 3: 171-92.
2. Babbitt BP, Allen PM, Matsueda G, et al. Binding of immunogenic peptides to Ia histocompatibility molecules. Nature 1985; 317: 359-61.
3. Zinkernagel RM, Doherty PC. Restriction ofin vitroT cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974; 248: 701-2.
4. Brigl M, Brenner MB. CD1: antigen presentation and T cell function. Annu Rev Immunol. 2004; 22: 817-90.
5. Sharma SD, Nag B, Su X, et al. Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes. Proc Natl Acad Sci USA. 1991; 88: 11465-9.
6. dfused to beta 2-microglobulin expressed in the baculovirus-insect cell system. J Biol Chem. 1992; 267: 24223-9.
7. Abastado JP, Lone YC, Casrouge A, et al. Dimerization of soluble major histocompatibility complex-peptide complexes is sufficient for activation of T cell hybridoma and induction of unresponsiveness. J Exp Med. 1995; 182: 439-47.
8. Kozono H, White J, Clements J, et al. Production of soluble MHC class II proteins with covalently bound single peptides. Nature 1994; 369: 151-4.
9. Weber S, Traunecker A, Oliveri F, et al. Specific low-affinity recognition of major histocompatibility complex plus peptide by soluble T-cell receptor. Nature 1992; 356: 793-6.
10. Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274: 94-6.
11. Hansen TH, Lybarger L. Exciting applications of single chain trimers of MHC-I molecules. Cancer Immunol Immunother. 2006; 55: 235-6.
12. Greten TF, Korangy F, Neumann G, et al. Peptide-beta 2 microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-I complexes. J Immunol Methods. 2002; 271: 125-35.
13. Nepom, GT, Erlich H. MHC class-II molecules and autoimmunity. Annu Rev Immunol. 1991; 9: 493-525.
14. Durai M, Krueger C, Ye Z, et al. In vivofunctional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC). Cancer Immunol Immunother. 2009; 58: 209-20.
15. Godfrey DI, MacDonald HR, Kronenberg M, et al. NKT cells: what's in a name? Nat Rev Immunol. 2004; 4: 231-7.
16. Vollers SS, Stern LJ. Class II major histocompatibility complex tetramer staining: progress, problems, and prospects. Immunology 2008; 123: 305-13.
17. Casares S, Bona CA, Brumeanu TD. Engineering and characterization of a murine MHC class II-immunoglobulin chimera expressing an immunodominant CD4 T viral epitope. Protein Eng. 1997; 10: 1295-301.
18. Lebowitz MS, O'Herrin SM, Hamad AR, et al. Soluble, high-affinity dimers of T-cell receptors and class II major histocompatibility complexes: biochemical probes for analysis and modulation of immune responses. Cell Immunol. 1999; 192: 175-84.
19. Davis MM, Boniface JJ, Reich Z, et al. Ligand recognition by alpha beta T cell receptors. Annu Rev Immunol. 1999; 16: 523-44.
20. Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsivenessin vitroandin vivo. J Exp Med. 1987; 165: 302-19.
21. Powell JD, Ragheb JA, Kitagawa-Sakakida S, et al. Molecular regulation of interleukin-2 expression by CD28 co-stimulation and anergy. Immunol Rev. 1998; 165: 287-300.
22. Preda I, McEvoy RC, Lin M, et al. Soluble, dimeric HLA DR4-peptide chimeras: an approach for detection and immunoregulation of human type-1 diabetes. Eur J Immunol. 2005; 35: 2762-75.
23. Wucherpfennig KW, Yu B, Bhol K, et al. Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Proc Natl Acad Sci USA. 1995; 92: 11935-9.
24. Hamad AR, O'Herrin SM, Lebowitz MS, et al. Potent T cell activation with dimeric peptide-major histocompatibility complex class II ligand: the role of CD4 co-receptor. J Exp Med. 1998; 188: 1633-40.
25. Masteller EL, Warren MR, Ferlin W, et al. Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes. J Immunol. 2003; 171: 5587-95.
26. Karabekian Z, Lytton SD, Silver PB, et al. Antigen/MHC class II/Ig dimers for study of uveitogenic T cells: IRBP p161-180 presented by both IA and IE molecules. Invest Ophthalmol Vis Sci. 2005; 46: 3769-76.
27. Lin M, Stoica-Nazarov C, Surls J, et al. Reversal of type 1 diabetes by a new MHC II-peptide chimera: "single-epitope mediated suppression" to stabilize a polyclonal autoimmune T-cell process. Eur J Immunol. 2010; 40: 2277-88.
28. Ratcliffe MJ, Coggeshall KM, Newell MK, et al. T cell receptor aggregation, but not dimerization, induces increased cytosolic calcium concentrations and reveals a lack of stable association between CD4 and the T cell receptor. J Immunol 1992; 148: 1643-51.
29. Reich Z, Boniface JJ, Lyons DS, et al. Ligand-specific oligomerization of T-cell receptor molecules. Nature 1997; 387: 617-20.
30. Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science 1996; 273: 104-6.
31. Schneck JP. Monitoring antigen-specific T cells using MHC-Ig dimers. Immunol Invest. 2000; 29: 63-9.
32. Doyle C, Strominger JL. Interaction between CD4 and class II MHC molecules mediates cell adhesion. Nature 1987; 330: 256-9.
33. Gay D, Maddon P, Sekaly R, et al. Functional interaction between human T-cell protein CD4 and the major histocompatibility complex HLA-DR antigen. Nature 1987; 328: 626-9.
34. Casares S, Zong CS, Radu DL, et al. Antigen-specific signaling by a soluble, dimeric peptide/major histocompatibility complex class II/Fc chimera leading to T helper cell type 2 differentiation. J Exp Med. 1999; 190: 543-53.
35. Bona C, Stevenson F. B cells producing pathogenic autoantibodies. In: Alt F, Honjo T, Neuberger M, editors. Molecular biology of B cells. The Netherlands Elsevier; 2004. p. 381-401.
36. Nicholson MJ, Hahn M, Wucherpfennig KW. Unusual features of self- peptide/MHC binding by autoimmune T cell receptors. Immunity 2005; 23: 351-60.
37. Kaladadze AM, Galleno M, Foncerrada JL, et al. Expression of recombinant HLA-DR2 molecules: replacememt of hydrophobic transmembrane region by a leucine zipper dimerization motif allow as the assemblay and secretion of soluble DRab heterodimers. J Bio Chem. 1996; 271: 20156-62.
38. Bradley LM, Asensio VC, Schoitz LK, et al. Islet-specific Th1, but not Th2, cells secrete multiple chemokines and promote rapid induction of autoimmune diabetis. J Immunol. 1999; 192: 2511-20.
39. Vizler C, Bercovic N, Cornet A, et al. Role of autoreactive CD8+ T cells in organ specific autoimmune diseases: insight in transgenic mice Imunnol Rev. 1999; 169: 81-92.
40. Gallichan WS, Balasa B, Davies JD, et al. Pancreatic IL-4 expression results in islet-reactive Th2 cells that inhibit diabetogenic lymphocytes in the nonobese diabetic mouse. J Immunol. 1999; 163: 1696-703.
41. Todd JA, Wicker LS. Genetic protection from the inflammatory disease type 1 diabetes in humans and animal models. Immunity 2001; 15: 387-95.
42. Fahmy TM, Bieler JG, Edidin M, et al. Increased TCR avidity after T cell activation: a mechanism for sensing low-density antigen. Immunity 2001; 14: 135-43.
43. Amrani A, Verdaguer J, Serra P, et al. Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature 2000; 406: 739-42.
44. Tisch R, Yang XD, Singer SM, et al. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 1993; 366: 72-5.
45. Serreze DV, Johnson EA, Chapman HD, et al. Autoreactive diabetogenic T-cells in NOD mice can efficiently expand from a greatly reduced precursor pool. Diabetes 2001; 50: 1992-2000.
46. Wicker LS, Miller BJ, Mullen Y. Transfer of autoimmune diabetes mellitus with splenocytes from nonobese diabetic (NOD) mice. Diabetes 1986; 35: 855-60.
47. Peterson JD, Pike B, McDuffie M, et al. Islet-specific T cell clones transfer diabetes to nonobese diabetic (NOD) F1 mice. J Immunol. 1994; 153: 2800-6.
48. + single positive cells with a class II major histocompatibility complex-restricted receptor. J Exp Med. 1994; 180: 25-34.
49. Radu DL, Brumeanu TD, McEvoy RC, et al. Escape from self-tolerance leads to neonatal insulin-dependent diabetes mellitus. Autoimmunity 1999; 30: 199-20.
50. + T cells by a soluble dimeric peptide-MHC class II chimera. Nature Immunol. 2002; 3: 383-91.
51. Barshes NR, Lee T, Goodpasture S, et al. Achievement of insulin independenceviapancreatic islet transplantation using a remote isolation center: a first-year review. Transplant Proc. 2004; 36: 1127-9.
52. Casares S, Lin M, Zhang N, et al. A peptide-major Histocompatibility complex II chimera favors survival of pancreatic (beta islets grafted in type 1 diabetic mice. Transplantation 2008; 285: 1717-27.
53. g7-dependent reaction. Proc Natl Acad Sci USA. 1998; 95: 1721-4.
54. Kaufman DL, Clare-Salzler M, Tian J, et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993; 366: 69-72.
55. + islet-specific T cell clone. Science 1990; 249: 1433-6.